TAKEDA PHARMA (TKD BE) stock market data APIs
€24.0098
0(0%)
as of October 24, 2025
Try our APIs with
free plan!
TAKEDA PHARMA Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for TKD.BE.
Prev. Close
24.0098
Open
24.0098
High
24.0098
Low
24.0098
52 wk Range
23.4219-27.1097
Market Cap
37 823 M
Dividends (Yield)
3.1842
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get TAKEDA PHARMA data using free add-ons & libraries
Get TAKEDA PHARMA Fundamental Data
TAKEDA PHARMA Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-30
- EPS/Forecast: 44.26
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
TAKEDA PHARMA News
New
Glomerulonephritis Market Projected to Surge by 2034 with Rising Demand for Targeted Therapies | DelveInsight
The glomerulonephritis market is witnessing steady growth driven by the increasing prevalence of chronic kidney diseases and improved diagnostic capabilities. Additionally, ongoing clinical trial acti...
Stifel Canada on Healwell AI's Darwen Platform
Healwell AI (AIDX.TO) this week, in collaboration with vedolizumab manufacturer, Takeda, presented n PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Health Care Roundup: Market Talk
HEALTH NEWS The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0757 GMT – The muted response to Innovent’s can...
China’s Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion
The tie-up is the latest between Chinese companies and international pharma majors looking to expand their global reach and tap promising drug pipelines developing in China. Continue Reading View Comments
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
